• Je něco špatně v tomto záznamu ?

An Ultrasensitive Biosensor for Detection of Femtogram Levels of the Cancer Antigen AGR2 Using Monoclonal Antibody Modified Screen-Printed Gold Electrodes

W. Białobrzeska, K. Dziąbowska, M. Lisowska, MA. Mohtar, P. Muller, B. Vojtesek, R. Krejcir, R. O'Neill, TR. Hupp, N. Malinowska, E. Bięga, D. Bigus, Z. Cebula, K. Pala, E. Czaczyk, S. Żołędowska, D. Nidzworski

. 2021 ; 11 (6) : . [pub] 20210607

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025600

The detection of cancer antigens is a major aim of cancer research in order to develop better patient management through early disease detection. Many cancers including prostate, lung, and ovarian secrete a protein disulfide isomerase protein named AGR2 that has been previously detected in urine and plasma using mass spectrometry. Here we determine whether a previously developed monoclonal antibody targeting AGR2 can be adapted from an indirect two-site ELISA format into a direct detector using solid-phase printed gold electrodes. The screen-printed gold electrode was surface functionalized with the anti-AGR2 specific monoclonal antibody. The interaction of the recombinant AGR2 protein and the anti-AGR2 monoclonal antibody functionalized electrode changed its electrochemical impedance spectra. Nyquist diagrams were obtained after incubation in an increasing concentration of purified AGR2 protein with a range of concentrations from 0.01 fg/mL to 10 fg/mL. In addition, detection of the AGR2 antigen can be achieved from cell lysates in medium or artificial buffer. These data highlight the utility of an AGR2-specific monoclonal antibody that can be functionalized onto a gold printed electrode for a one-step capture and quantitation of the target antigen. These platforms have the potential for supporting methodologies using more complex bodily fluids including plasma and urine for improved cancer diagnostics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025600
003      
CZ-PrNML
005      
20211026133651.0
007      
ta
008      
211013s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/bios11060184 $2 doi
035    __
$a (PubMed)34200338
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Białobrzeska, Wioleta $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
245    13
$a An Ultrasensitive Biosensor for Detection of Femtogram Levels of the Cancer Antigen AGR2 Using Monoclonal Antibody Modified Screen-Printed Gold Electrodes / $c W. Białobrzeska, K. Dziąbowska, M. Lisowska, MA. Mohtar, P. Muller, B. Vojtesek, R. Krejcir, R. O'Neill, TR. Hupp, N. Malinowska, E. Bięga, D. Bigus, Z. Cebula, K. Pala, E. Czaczyk, S. Żołędowska, D. Nidzworski
520    9_
$a The detection of cancer antigens is a major aim of cancer research in order to develop better patient management through early disease detection. Many cancers including prostate, lung, and ovarian secrete a protein disulfide isomerase protein named AGR2 that has been previously detected in urine and plasma using mass spectrometry. Here we determine whether a previously developed monoclonal antibody targeting AGR2 can be adapted from an indirect two-site ELISA format into a direct detector using solid-phase printed gold electrodes. The screen-printed gold electrode was surface functionalized with the anti-AGR2 specific monoclonal antibody. The interaction of the recombinant AGR2 protein and the anti-AGR2 monoclonal antibody functionalized electrode changed its electrochemical impedance spectra. Nyquist diagrams were obtained after incubation in an increasing concentration of purified AGR2 protein with a range of concentrations from 0.01 fg/mL to 10 fg/mL. In addition, detection of the AGR2 antigen can be achieved from cell lysates in medium or artificial buffer. These data highlight the utility of an AGR2-specific monoclonal antibody that can be functionalized onto a gold printed electrode for a one-step capture and quantitation of the target antigen. These platforms have the potential for supporting methodologies using more complex bodily fluids including plasma and urine for improved cancer diagnostics.
650    _2
$a monoklonální protilátky $7 D000911
650    12
$a biosenzitivní techniky $7 D015374
650    _2
$a elektrochemické techniky $7 D055664
650    _2
$a elektrody $7 D004566
650    _2
$a zlato $7 D006046
650    _2
$a lidé $7 D006801
650    _2
$a limita detekce $7 D057230
650    _2
$a kovové nanočástice $7 D053768
650    _2
$a mukoproteiny $x analýza $7 D009088
650    _2
$a nádory $7 D009369
650    _2
$a onkogenní proteiny $x analýza $7 D015513
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dziąbowska, Karolina $u SensDx, 14b Postępu St., 02-676 Warszawa, Poland
700    1_
$a Lisowska, Małgorzata $u International Centre for Cancer Vaccine Science, University of Gdansk, Kładki 24 St., 80-822 Gdańsk, Poland
700    1_
$a Mohtar, M Aiman $u UKM Medical Centre, UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia
700    1_
$a Muller, Petr $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 65653 Brno, Czech Republic
700    1_
$a Vojtesek, Borivoj $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 65653 Brno, Czech Republic
700    1_
$a Krejcir, Radovan $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 65653 Brno, Czech Republic
700    1_
$a O'Neill, Robert $u Cambridge Oesophagogastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
700    1_
$a Hupp, Ted R $u International Centre for Cancer Vaccine Science, University of Gdansk, Kładki 24 St., 80-822 Gdańsk, Poland $u Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XR, UK
700    1_
$a Malinowska, Natalia $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
700    1_
$a Bięga, Ewelina $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
700    1_
$a Bigus, Daniel $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
700    1_
$a Cebula, Zofia $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
700    1_
$a Pala, Katarzyna $u SensDx, 14b Postępu St., 02-676 Warszawa, Poland
700    1_
$a Czaczyk, Elżbieta $u SensDx, 14b Postępu St., 02-676 Warszawa, Poland
700    1_
$a Żołędowska, Sabina $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
700    1_
$a Nidzworski, Dawid $u Institute of Biotechnology and Molecular Medicine, 3 Trzy Lipy St., 80-172 Gdansk, Poland
773    0_
$w MED00197236 $t Biosensors $x 2079-6374 $g Roč. 11, č. 6 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34200338 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133657 $b ABA008
999    __
$a ok $b bmc $g 1714583 $s 1146107
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 6 $e 20210607 $i 2079-6374 $m Biosensors $n Biosensors (Basel) $x MED00197236
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace